These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 31371191

  • 1. Real-world outcomes of rivaroxaban treatment in patients with nonvalvular atrial fibrillation and worsening renal function.
    Nakagawara J, Ikeda T, Ogawa S, Kitazono T, Minematsu K, Miyamoto S, Murakawa Y, Takeichi M, Kidani Y, Okayama Y, Sunaya T, Sato S, Yamanaka S.
    J Cardiol; 2019 Dec; 74(6):501-506. PubMed ID: 31371191
    [Abstract] [Full Text] [Related]

  • 2. Real-world outcomes of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS).
    Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Minematsu K, Miyamoto S, Murakawa Y, Takeichi M, Ohashi Y, Okayama Y, Sunaya T, Yamanaka S.
    J Cardiol; 2019 Jul; 74(1):60-66. PubMed ID: 30745002
    [Abstract] [Full Text] [Related]

  • 3. Real-World Outcomes of Rivaroxaban Treatment in Patients with Both Nonvalvular Atrial Fibrillation and a History of Ischemic Stroke/Transient Ischemic Attack.
    Minematsu K, Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Miyamoto S, Murakawa Y, Takeichi M, Kidani Y, Okayama Y, Sunaya T, Sato S, Yamanaka S.
    Cerebrovasc Dis; 2019 Jul; 48(1-2):53-60. PubMed ID: 31578012
    [Abstract] [Full Text] [Related]

  • 4. Real-world outcomes of rivaroxaban treatment in elderly Japanese patients with nonvalvular atrial fibrillation.
    Kitazono T, Ikeda T, Ogawa S, Nakagawara J, Minematsu K, Miyamoto S, Murakawa Y, Cavaliere M, Hayashi Y, Kidani Y, Okayama Y, Sunaya T, Sato S, Yamanaka S.
    Heart Vessels; 2020 Mar; 35(3):399-408. PubMed ID: 31492970
    [Abstract] [Full Text] [Related]

  • 5. On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF.
    Fordyce CB, Hellkamp AS, Lokhnygina Y, Lindner SM, Piccini JP, Becker RC, Berkowitz SD, Breithardt G, Fox KA, Mahaffey KW, Nessel CC, Singer DE, Patel MR, ROCKET AF Steering Committee and Investigators.
    Circulation; 2016 Jul 05; 134(1):37-47. PubMed ID: 27358435
    [Abstract] [Full Text] [Related]

  • 6. Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan.
    Miyamoto S, Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Minematsu K, Murakawa Y, Iwashiro S, Takeichi M, Kidani Y, Okayama Y, Sunaya T, Sato S, Yamanaka S.
    J Stroke Cerebrovasc Dis; 2020 Apr 05; 29(4):104584. PubMed ID: 31983518
    [Abstract] [Full Text] [Related]

  • 7. Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis.
    Sakuma I, Uchiyama S, Atarashi H, Inoue H, Kitazono T, Yamashita T, Shimizu W, Ikeda T, Kamouchi M, Kaikita K, Fukuda K, Origasa H, Shimokawa H.
    Heart Vessels; 2019 Nov 05; 34(11):1839-1851. PubMed ID: 31127325
    [Abstract] [Full Text] [Related]

  • 8. Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings.
    Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Minematsu K, Miyamoto S, Murakawa Y, Iwashiro S, Kidani Y, Okayama Y, Sunaya T, Sato S, Yamanaka S.
    J Thromb Thrombolysis; 2019 Nov 05; 48(4):653-660. PubMed ID: 31432451
    [Abstract] [Full Text] [Related]

  • 9. Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation.
    Murakawa Y, Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Minematsu K, Miyamoto S, Hayashi Y, Kidani Y, Okayama Y, Sunaya T, Sato S, Yamanaka S.
    Heart Vessels; 2020 Aug 05; 35(8):1125-1134. PubMed ID: 32253531
    [Abstract] [Full Text] [Related]

  • 10. Real-world safety and effectiveness of rivaroxaban using Japan-specific dosage during long-term follow-up in patients with atrial fibrillation: XAPASS.
    Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Minematsu K, Miyamoto S, Murakawa Y, Iwashiro S, Okayama Y, Sunaya T, Hirano K, Hayasaki T.
    PLoS One; 2021 Aug 05; 16(6):e0251325. PubMed ID: 34115769
    [Abstract] [Full Text] [Related]

  • 11. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.
    Laliberté F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, Damaraju CV, Schein JR, Lefebvre P.
    Curr Med Res Opin; 2014 Jul 05; 30(7):1317-25. PubMed ID: 24650301
    [Abstract] [Full Text] [Related]

  • 12. The EXPAND study: Efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation.
    Shimokawa H, Yamashita T, Uchiyama S, Kitazono T, Shimizu W, Ikeda T, Kamouchi M, Kaikita K, Fukuda K, Origasa H, Sakuma I, Saku K, Okumura Y, Nakamura Y, Morimoto H, Matsumoto N, Tsuchida A, Ako J, Sugishita N, Shimizu S, Atarashi H, Inoue H.
    Int J Cardiol; 2018 May 01; 258():126-132. PubMed ID: 29429636
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
    Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, Breithardt G, Singer DE, Becker RC, Hacke W, Paolini JF, Nessel CC, Mahaffey KW, Califf RM, Fox KA, ROCKET AF Steering Committee and Investigators.
    Circulation; 2014 Jul 08; 130(2):138-46. PubMed ID: 24895454
    [Abstract] [Full Text] [Related]

  • 14. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
    Li G, Lip GYH, Holbrook A, Chang Y, Larsen TB, Sun X, Tang J, Mbuagbaw L, Witt DM, Crowther M, Thabane L, Levine MAH.
    Eur J Epidemiol; 2019 Feb 08; 34(2):173-190. PubMed ID: 29948370
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Design and baseline characteristics of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS).
    Ogawa S, Minematsu K, Ikeda T, Kitazono T, Nakagawara J, Miyamoto S, Murakawa Y, Ohashi Y, Takeichi M, Okayama Y, Yamanaka S, Inuyama L.
    J Arrhythm; 2018 Apr 08; 34(2):167-175. PubMed ID: 29657592
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.